Alexander Davis
@alexanderdavis.bsky.social
Medical Oncologist
PhD candidate - all things KRAS and lung cancer
PhD candidate - all things KRAS and lung cancer
www.theguardian.com/australia-ne...
This is great
This is great
Journal accepts bogus paper requesting removal from mailing list
Australian computer scientist Dr Peter Vamplew submitted emphatically titled paper to ‘predatory’ journal and ‘nearly fell off chair’ when it was accepted
www.theguardian.com
March 26, 2025 at 7:57 AM
www.theguardian.com/australia-ne...
This is great
This is great
Reposted by Alexander Davis
A story of controversy: During my time as Reviews Editor at the Journal of Thoracic Oncology, Alex Adjei, the editor -in-chief accepted my pitch to have these pro/cons. Inspired by some of the sport seen in fun conference debates. www.sciencedirect.com/science/arti...
Adjuvant Immunotherapy Should Not be Used in Patients With a Pathologic Complete Response to Neoadjuvant Chemoimmunotherapy
www.sciencedirect.com
January 9, 2025 at 7:36 PM
A story of controversy: During my time as Reviews Editor at the Journal of Thoracic Oncology, Alex Adjei, the editor -in-chief accepted my pitch to have these pro/cons. Inspired by some of the sport seen in fun conference debates. www.sciencedirect.com/science/arti...
Reposted by Alexander Davis
Press release: MARIPOSA regimen of first-line amivantamab plus lazertinib shows a significant improvement in overall survival over osimertinib alone in #EGFR NSCLC. Full data to be presented but improvement in median OS expected to be over 12 months.
www.jnj.com/media-center...
www.jnj.com/media-center...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) shows statistically significant and clinically meaningful improvement in overall survival versus osimertinib
Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer
www.jnj.com
January 7, 2025 at 1:34 PM
Press release: MARIPOSA regimen of first-line amivantamab plus lazertinib shows a significant improvement in overall survival over osimertinib alone in #EGFR NSCLC. Full data to be presented but improvement in median OS expected to be over 12 months.
www.jnj.com/media-center...
www.jnj.com/media-center...